Dr Reddy's files new drug application for migraine spray with USFDA
Upon approval, the product will be commercialised by Promius Pharma
 "Dr Reddy's files new drug application for migraine spray with USFDA")
premium
Dr Reddy's Laboratories Limited and its subsidiary, Promius Pharma, LLC, on Monday announced the filing of new drug application (NDA) for its migraine candidate DFN-02 with the US Food and Drug Administration(US FDA).
DFN-02 is a novel intranasal spray formulation currently patented in 11 countries, composed of sumatriptan and permeation-enhancing technology known as Infravail of Aegis Therapeutics, LLC.
"The filing of DFN-02 represents our continuing commitment to bring innovative solutions in migraine treatment," said Anil Nmboodripad, senior vice president, proprietary products and president, Promius Pharma.
Upon approval, the product will be commercialised by Promius Pharma.
One subscription. Two world-class reads.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%